NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period").

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Micron Technology, Inc. ("Micron" or "the Company") (NASDAQ:MU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Micron securities between September 28, 2023 and December 18, 2024, both dates inclusive (the "Class Period").

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period").

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Transocean Ltd. ("Transocean" or "the Company") (NYSE:RIG) and certain of its officers.

Move expected to broaden access to Ekso Bionics' portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United States Move expected to broaden access to Ekso Bionics' portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United States

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones.

PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024.

Tilray Brands Enhances Global Cannabis Supply Chain Increases Industry-Leading Capacity to Meet Global Demand, Driving Growth Across Canada and Europe

Boca Raton, Florida, Feb. 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) , a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announced today, following a Type C meeting with the U.S. Food and Drug Administration (FDA), its intent to submit a BLA in the US and Marketing Authorization Application (MAA) in the UK and EU supported by data from the MissionEB clinical trial investigating CORDStrom as a disease-modifying therapy for treating RDEB in pediatric patients.

KITCHENER, ON , Feb. 10, 2025 /PRNewswire/ -- Canadian Solar Inc. (the "Company" or "Canadian Solar") (NASDAQ: CSIQ) today announced that e-STORAGE, which is part of the Company's majority-owned subsidiary CSI Solar Co., Ltd. ("CSI Solar"), has signed a contract with Copenhagen Infrastructure Partners ("CIP") through its fifth flagship fund Copenhagen Infrastructure V to deliver 240 MW/960 MWh battery energy storage systems in Summerfield, South Australia.

Q3 revenue rises to $106 million, an increase of 45% year-over-year, with service revenuerepresenting 77% of total revenue Adjusted EBITDA climbs to $22 million, an increase of 77%, driving an annual run ratesurpassing $85 million— doubling 2024 adjusted EBITDA FY25 full year guidance increased $10 million for revenue and $2.5 million for adjustedEBITDA Meaningful increase in adjusted gross margin performance, with total adjusted grossmargins now above 60%, and adjusted service gross margins approaching 70% Post-M&A integration ahead of schedule, priming for double digit growth trajectory in FY26 WOODCLIFF LAKE, N.J. , Feb. 10, 2025 /PRNewswire/ -- Powerfleet, Inc. (Nasdaq: AIOT) …

NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ:ATRA). Investors who purchased Atara securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ATRA.

SHOEMAKERSVILLE, Pa., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (Nasdaq: HYFM) (“Hydrofarm” or the “Company”) today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on February 12, 2025. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on February 13, 2025, under the Company's existing trading symbol “HYFM.”

SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today.

Glass Lewis Finds Matthews Has "Persistently Deteriorated and Consistently Underperformed During Substantially All Measurement Periods, Including During the Fullness of Mr. Bartolacci's Tenure as CEO" Asserts Barington "Has Offered Investors a Reasonable, Credible and Incremental Slate of Candidates" and a "More Promising Roadmap" for the Company Recommends Shareholders Vote "WITHHOLD" on Matthews' Nominees Terry L.

Global Systemwide sales* were over $130 billion for the full year, with full year growth of more than $1 billion (more than $2 billion in constant currencies) Systemwide sales to loyalty members were approximately $30 billion for the full year and approximately $8 billion for the quarter across 60 loyalty markets, with full year growth of 30% over prior year 90-day active loyalty users were over 175 million across 60 loyalty markets as of year-end, with growth of approximately 15% over prior year CHICAGO , Feb. 10, 2025 /PRNewswire/ -- McDonald's Corporation today announced results for the fourth quarter and …

The Keynote Titled ״Is the future of video processing destined for GPU?״ Describes First Hand The Evolution of Video Encoding in the Past Decades Herzliya Israel, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beamr Imaging Ltd.

Streamlining the Referral Process to Enhance Efficiency and Patient Experience SOMERSET, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO, CCLDP), a leader in healthcare technology and AI-driven solutions, is proud to announce the launch of its new advanced referral module.

Gross Profit Increased 23.5% from the Previous Year to $7.7 million Gross Margins Increased to 18.5%, up from 15.0% the Previous Year Revenue Increased 0.3% Year-Over-Year to $41.8 Million LOS ANGELES , Feb. 10, 2025 /PRNewswire/ -- Ispire Technology Inc. ( NASDAQ: ISPR ) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported results for the fiscal second quarter 2025, which ended on December 31, 2024. Fiscal Second Quarter 2025 Financial Results Revenue of $41.8 million, compared to $41.7 million for the fiscal second quarter of 2024.

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). “We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion's CEO. “Don's track record of strategic and operational financial leadership, coupled.